Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.38 |
| ▸ | MME | P08473 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 2/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 4/20 | 0.36 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.36 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7612828 | 1.00 | ACE (0.38) | ACEMMECASP3DDB1CRBN | |
| SCHEMBL7615477 | 1.00 | ACE (0.38) | ACEMMECASP3DDB1CRBN | |
| SCHEMBL10566940 | 0.94 | DDB1 (0.38) | ACEMMECASP3DDB1CRBN | |
| SCHEMBL10566783 | 0.94 | DDB1 (0.38) | ACEMMECASP3DDB1CRBN | |
| SCHEMBL10561930 | 0.92 | CASP3 (0.39) | ACEMMECASP3DDB1CRBN | |
| SCHEMBL7158797 | 0.89 | MME (0.41) | ACEMMEDDB1CRBNALDH1A1 | |
| SCHEMBL7034916 | 0.89 | MME (0.41) | ACEMMEDDB1CRBNALDH1A1 | |
| SCHEMBL3264771 | 0.86 | CASP3 (0.40) | ACEMMECASP3DDB1CRBN | |
| SCHEMBL10201276 | 0.85 | CASP3 (0.39) | CASP3DDB1CRBNALDH1A1CHRM2 | |
| SCHEMBL10248861 | 0.85 | CASP3 (0.39) | CASP3DDB1CRBNALDH1A1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6433164-B1 | — | — | None | — | — | US | disclosed |
| EP-2791161-B1 | INHIBITORS OF HCV NS5A | HOFFMANN LA ROCHE (CH) | 2016-02-10 | — | — | EP | disclosed |
| EP-2791161-B1 | INHIBITORS OF HCV NS5A | HOFFMANN LA ROCHE (CH) | 2016-02-10 | — | — | EP | disclosed |
| US-9180193-B2 | Antiviral compounds | HOFFMANN-LA ROCHE INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9180193-B2 | Antiviral compounds | HOFFMANN-LA ROCHE INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9180193-B2 | Antiviral compounds | HOFFMANN-LA ROCHE INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9133170-B2 | Inhibitors of HCV NS5A | HOFFMANN-LA ROCHE INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133170-B2 | Inhibitors of HCV NS5A | HOFFMANN-LA ROCHE INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133170-B2 | Inhibitors of HCV NS5A | HOFFMANN-LA ROCHE INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20150166514-A1 | INHIBITORS OF HCV NS5A | HOFFMANN-LA ROCHE INC. (US) | 2015-06-18 | — | — | US | disclosed |
| WO-2013087743-A1 | INHIBITORS OF HCV NS5A | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-20 | — | — | WO | disclosed |
| WO-2013053657-A1 | ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-04-18 | — | — | WO | disclosed |
| US-20120328565-A1 | ANTIVIRAL COMPOUNDS | BRINKMAN JOHN A (US) | 2012-12-27 | — | — | US | disclosed |
| US-20120230951-A1 | ANTIVIRAL COMPOUNDS | ALAM MUZAFFAR (US) | 2012-09-13 | — | — | US | disclosed |
| US-6433164-B2 | SUBSTITUTED ON RING CARBON #9 BY A PRIMARY AMINE WHICH MAY OR MAY NOT BE PROTECTED; DEHYDROGENATION OF THE OCTOHYDRO DERIVATIVE; DRUGS | AVENTIS PHARMA S.A. (FR) | 2002-08-13 | — | — | US | disclosed |
| US-20010002422-A1 | (3,4,7,8,9,10-hexahydro-6, 10 -6H-pyridazino [1,2-a] [1,2,] diazepine-1-carboxylic-acid derivatives | HOECHST MARION ROUSSEL | 2001-05-31 | — | — | US | disclosed |
| US-4808713-A | Anthypertensive pyridazo [1,2-a][1,2]diazepines | HOFFMAN-LA ROCHE INC. (US) | 1989-02-28 | — | — | US | disclosed |
| US-4772701-A | Pyridazo[1,2]pyridazines and pyrazolo[1,2]pyridazines as antihypertensives | HOFFMANN-LA ROCHE INC. (US) | 1988-09-20 | — | — | US | disclosed |
| US-4658024-A | Pyrazolo [1,2-a][1,2]-diazepines useful as antihypertensives | HOFFMANN-LA ROCHE INC. (US) | 1987-04-14 | — | — | US | disclosed |
| US-4512924-A | HYPOTENSIVE AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1985-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010002422-A1 | (3,4,7,8,9,10-hexahydro-6, 10 -6H-pyridazino [1,2-a] [1,2,] diazepine-1-carboxylic-acid derivatives | GRIK1, GRIK2, ATXN2L | ACE 1357/4885MME 4589/4885CASP3 914/4885 |
| US-20120328565-A1 | ANTIVIRAL COMPOUNDS | EIF2AK2, HAVCR2, MAVS | ACE 104/4885MME 1409/4885CASP3 1970/4885 |
| US-20120230951-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | ACE 79/4885MME 503/4885CASP3 634/4885 |
| US-20150166514-A1 | INHIBITORS OF HCV NS5A | HAVCR2, EIF2AK2, MAVS | ACE 1102/4885MME 729/4885CASP3 4006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.